Shares of ICU Medical Inc. (NASDAQ:ICUI) have been given an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.
Brokerages have set a one year consensus price target of $128.50 for the company and are forecasting that the company will post $0.92 earnings per share for the current quarter, according to Zacks. Zacks has also given ICU Medical an industry rank of 106 out of 265 based on the ratings given to its competitors.
A number of equities research analysts have recently commented on the company. Piper Jaffray Cos. reissued a “neutral” rating and issued a $119.00 target price (up from $115.00) on shares of ICU Medical in a research note on Thursday, August 11th. Zacks Investment Research raised ICU Medical from a “hold” rating to a “buy” rating and set a $140.00 price target on the stock in a report on Friday, August 12th.
In other ICU Medical news, VP Steven Riggs sold 20,000 shares of the stock in a transaction dated Wednesday, June 29th. The stock was sold at an average price of $110.00, for a total value of $2,200,000.00. Following the transaction, the vice president now owns 21,378 shares of the company’s stock, valued at $2,351,580. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Vivek Jain sold 7,268 shares of the stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $124.25, for a total value of $903,049.00. Following the completion of the transaction, the chairman now directly owns 48,497 shares in the company, valued at approximately $6,025,752.25. The disclosure for this sale can be found here. Insiders own 15.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its position in ICU Medical by 4.3% in the second quarter. BlackRock Fund Advisors now owns 931,445 shares of the company’s stock worth $105,020,000 after buying an additional 38,161 shares in the last quarter. Renaissance Technologies LLC increased its position in ICU Medical by 3.6% in the first quarter. Renaissance Technologies LLC now owns 842,000 shares of the company’s stock worth $87,652,000 after buying an additional 29,200 shares in the last quarter. FMR LLC increased its position in ICU Medical by 11.0% in the second quarter. FMR LLC now owns 602,812 shares of the company’s stock worth $67,967,000 after buying an additional 59,976 shares in the last quarter. Silvercrest Asset Management Group LLC increased its position in ICU Medical by 12.2% in the second quarter. Silvercrest Asset Management Group LLC now owns 575,561 shares of the company’s stock worth $64,894,000 after buying an additional 62,638 shares in the last quarter. Finally, GW&K Investment Management LLC increased its position in ICU Medical by 0.5% in the second quarter. GW&K Investment Management LLC now owns 542,184 shares of the company’s stock worth $61,131,000 after buying an additional 2,798 shares in the last quarter. 89.50% of the stock is currently owned by institutional investors.
Shares of ICU Medical (NASDAQ:ICUI) traded up 0.60% during mid-day trading on Tuesday, hitting $126.25. 37,592 shares of the stock traded hands. ICU Medical has a 52 week low of $85.56 and a 52 week high of $128.93. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of 37.60 and a beta of 0.49. The firm’s 50-day moving average is $124.38 and its 200-day moving average is $110.49.
ICU Medical (NASDAQ:ICUI) last released its earnings results on Monday, August 8th. The company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. ICU Medical had a return on equity of 10.33% and a net margin of 14.94%. The firm had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $89.66 million. During the same period in the prior year, the firm posted $0.97 earnings per share. The company’s quarterly revenue was up 15.4% on a year-over-year basis. On average, analysts forecast that ICU Medical will post $4.54 earnings per share for the current year.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.